- Home
- OBIO vs AVIR Comparison
OBIO vs AVIR Comparison
Compare OBIO & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OBIO | AVIR |
|---|---|---|
| Founded | 2017 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 237.2M | 236.7M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | OBIO | AVIR |
|---|---|---|
| Price | $4.32 | $3.65 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 1 |
| Target Price | ★ $14.00 | $6.00 |
| AVG Volume (30 Days) | 202.4K | ★ 371.5K |
| Earning Date | 11-10-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,818,000.00 | N/A |
| Revenue This Year | $35.75 | N/A |
| Revenue Next Year | $3.07 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 6.46 | N/A |
| 52 Week Low | $2.20 | $2.46 |
| 52 Week High | $6.30 | $4.02 |
Technical Indicators
Market Signals| Indicator | OBIO | AVIR |
|---|---|---|
| Relative Strength Index (RSI) | 48.23 | 71.27 |
| Support Level | $4.07 | $3.11 |
| Resistance Level | $4.47 | $3.72 |
| Average True Range (ATR) | 0.25 | 0.12 |
| MACD | -0.05 | 0.06 |
| Stochastic Oscillator | 40.80 | 90.24 |
Price Performance
Historical ComparisonAbout OBIO Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).